You are here

Specialized Health Care May Be Lacking Under ACA Plans

Many enrollees appear to lack access to in-network specialists, study warns

New research shows that many health plans sold through the Affordable Care Act (ACA) in 2015 do not offer patients access to some medical specialists, such as endocrinologists, rheumatologists, and psychiatrists.

Under the ACA, the federal marketplace offers subsidized private health insurance to consumers in states that didn't establish their own health insurance exchanges. About one in seven health insurance plans offered on the federal marketplace in 2015 did not provide access to in-network doctors for at least one medical specialty, according to research reported by Reuters. 

"People need to be really mindful of what they’re actually getting with their plans," said lead author Stephen Dorner, of the Harvard T.H. Chan School of Public Health in Boston. He and his colleagues write in the Journal of the American Medical Association that nearly 12 million Americans gained health insurance through the 2010 law's marketplaces. By law, insurance plans are supposed to ensure "reasonable access" to providers.

For the study, the researchers looked at 135 health insurance plans in 34 state marketplaces that were available during the 2015 open enrollment period, when people can select their plans.

Using the plans' physician directories, they looked for in-network specialists who would be covered by insurance, including obstetricians/gynecologists, dermatologists, cardiologists, psychiatrists, oncologists, neurologists, endocrinologists, rheumatologists, and pulmonologists. Overall, in April 2015, 18 plans in nine states lacked in-network specialists for at least one specialty within a 100-mile search area, and 19 lacked specialists within a 50-mile radius.

Endocrinology, rheumatology, and psychiatry were the most commonly excluded specialties. Another seven to 14 plans had fewer than five in-network doctors in those fields.

When the researchers repeated their search in May, six of the 19 plans lacking specialists had added more providers.

The researchers also found that people enrolled in plans that lacked access to specialists had high out-of-network charges for doctors' visits and medication. In some cases, they had to pay half or more of all costs. "What this basically translates into is huge out-of-pocket costs for the consumers," Dorner said.

Clare Krusing, the press secretary for America's Health Insurance Plans, told Reuters Health by email that the new research ignored state standards for time and distance requirements. Also, Krusing said, the researchers did not account for the number of specialists operating in specific states, and didn't acknowledge that plans have processes and programs in place to ensure patient access.

"The study's limitations speak for themselves, and account for the fact that the report presents a misleading picture of what's happening in the market today," she said. "Health plans must meet state and federal network adequacy requirements that ensure patients have a wide range of providers and specialists available to them."

The researchers say the study relied on network directories, which are known to overestimate in-network providers. They add that the problem of access to in-network specialists may be even worse in rural areas.

"I think on the consumer side, they need to be really watchful of what is actually contained in their plans and what they’re getting," Dorner said. Additionally, he said the terms to evaluate plans should be better defined and existing regulations should be enforced.

Source: Reuters, October 27, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks